LU90866I2 - Hydrochlorure de sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorurede sibutramine - Google Patents

Hydrochlorure de sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorurede sibutramine

Info

Publication number
LU90866I2
LU90866I2 LU90866C LU90866C LU90866I2 LU 90866 I2 LU90866 I2 LU 90866I2 LU 90866 C LU90866 C LU 90866C LU 90866 C LU90866 C LU 90866C LU 90866 I2 LU90866 I2 LU 90866I2
Authority
LU
Luxembourg
Prior art keywords
sibutramine hydrochloride
derivatives
pharmaceutically acceptable
acceptable salts
monohydrate
Prior art date
Application number
LU90866C
Other languages
English (en)
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23060006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90866(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of LU90866I2 publication Critical patent/LU90866I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU90866C 1988-11-29 2001-12-18 Hydrochlorure de sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorurede sibutramine LU90866I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27724088A 1988-11-19 1988-11-19

Publications (1)

Publication Number Publication Date
LU90866I2 true LU90866I2 (fr) 2002-02-18

Family

ID=23060006

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90866C LU90866I2 (fr) 1988-11-29 2001-12-18 Hydrochlorure de sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorurede sibutramine

Country Status (15)

Country Link
US (1) US5436272A (fr)
EP (1) EP0397831B1 (fr)
JP (1) JPH06102622B2 (fr)
KR (1) KR0164435B1 (fr)
AU (1) AU633529B2 (fr)
CA (1) CA2003524C (fr)
DE (2) DE19975039I2 (fr)
DK (1) DK175587B1 (fr)
IE (1) IE61928B1 (fr)
IL (1) IL92406A (fr)
LU (1) LU90866I2 (fr)
NL (1) NL300066I2 (fr)
PH (1) PH26677A (fr)
WO (1) WO1990006110A1 (fr)
ZA (1) ZA899058B (fr)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
AU721924B2 (en) * 1992-06-23 2000-07-20 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
WO1994000114A1 (fr) * 1992-06-23 1994-01-06 Sepracor Inc. Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (-) optiquement pure
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
WO2000056309A1 (fr) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Procede de traitement de troubles de la sexualite
AU3894500A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Prevention of cardiovascular disease
CA2367022A1 (fr) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Traitement de l'apnee du sommeil
AU3895400A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Control of metabolism
JP2002539250A (ja) 1999-03-19 2002-11-19 クノール・ゲー・エム・ベー・ハー 肺高血圧症の治療
AU3895300A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
CA2366660A1 (fr) * 1999-03-19 2000-09-28 Carl M. Mendel Traitement de l'arthrose
WO2000056321A1 (fr) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Traitement de l'hyperactivite
SK13362001A3 (sk) * 1999-03-19 2002-07-02 Knoll Gmbh Použitie zlúčeniny a farmaceutická kompozícia ju obsahujúca
CA2368416A1 (fr) * 1999-03-19 2000-09-28 Knoll Gmbh Traitement des calculs biliaires
WO2000054765A1 (fr) * 1999-03-19 2000-09-21 Knoll Gmbh Traitement des troubles de l'alimentation
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
MXPA01009467A (es) * 1999-03-19 2004-03-19 Knoll Gmbh Metodo para controlar el aumento de peso asociado con farmacos terapeuticos.
US6365632B1 (en) 1999-03-19 2002-04-02 Knoll Pharmaceuticals Company Treatment of orthostatic hypotension
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
GB9926251D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Pharmaceutical formulation
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
AU2001282913A1 (en) * 2000-09-08 2002-03-22 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
FR2814678B1 (fr) † 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
US20020091114A1 (en) 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
WO2002083631A1 (fr) * 2001-04-13 2002-10-24 Sepracor Inc. Procedes permettant la preparation de didesmethylsibutramine et d'autres derives de sibutramine
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
ATE486842T1 (de) * 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
JP4765627B2 (ja) 2003-09-22 2011-09-07 Ｍｓｄ株式会社 新規ピペリジン誘導体
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7432398B2 (en) 2005-01-06 2008-10-07 Cj Corporation Inorganic acid salts of sibutramine
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US8138206B2 (en) 2005-05-30 2012-03-20 Msd. K.K. Piperidine derivative
CA2618112A1 (fr) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Compose de pyridone
WO2007024004A1 (fr) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Dérivé phénylpyridone
AU2006288153A1 (en) 2005-09-07 2007-03-15 Msd K.K. Bicyclic aromatic substituted pyridone derivative
EP1938811A4 (fr) * 2005-09-22 2008-12-17 Eisai R&D Man Co Ltd Préparation thérapeutique pour le traitement de la boulimie et de la dépression associée à la boulimie
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
RU2008119687A (ru) 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
CA2627139A1 (fr) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Nouveau derive de benzoxathiine
ES2381205T3 (es) 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
UA100497C2 (ru) 2006-09-07 2013-01-10 Никомед Гмбх Комбинированное лечение сахарного диабета
EP2066329B1 (fr) * 2006-09-15 2017-09-06 Reviva Pharmaceuticals, Inc. Synthèse, utilisation et compositions de cyclobutylméthylamines
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008047544A1 (fr) 2006-09-28 2008-04-24 Banyu Pharmaceutical Co., Ltd. Dérivé diarylcétimine
CA2681449A1 (fr) * 2007-04-09 2008-10-16 Scidose, Llc Combinaisons de statines et d'agent anti-obesite
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
KR101560844B1 (ko) 2007-06-04 2015-10-15 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 트라이-아릴계 화합물 및 이를 포함하는 조성물
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
EP2810951B1 (fr) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
CA2730603C (fr) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase utiles dans le traitement des affections gastro-intestinales, de l'inflammation gastro-intestinale, du cancer gastro-intestinal et d'autres affections
JPWO2010013595A1 (ja) 2008-07-30 2012-01-12 Ｍｓｄ株式会社 ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体
EP2348857B1 (fr) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
WO2010065889A2 (fr) * 2008-12-06 2010-06-10 Auspex Pharmaceutical Inhibiteurs cyclobutaneméthanamine de la réabsorption de monoamine
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012003501A2 (fr) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthèse et procédés d'utilisation de dérivés de cycloalkylméthylamine
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
WO2014022528A1 (fr) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
WO2014130608A1 (fr) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Composés bicycliques antidiabétiques
WO2014139388A1 (fr) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
EA201690938A1 (ru) 2013-11-05 2016-11-30 Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания
EP3186242B1 (fr) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique
AU2017342083A1 (en) 2016-10-14 2019-04-11 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (fr) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Composés de spirochromane antidiabétiques
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
GB2184122B (en) * 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment

Also Published As

Publication number Publication date
JPH02503682A (ja) 1990-11-01
HK1006002A1 (en) 1999-02-05
JPH06102622B2 (ja) 1994-12-14
ZA899058B (en) 1990-08-29
NL300066I2 (nl) 2002-06-03
EP0397831B1 (fr) 1993-09-15
IL92406A (en) 1995-07-31
DE68909219D1 (de) 1993-10-21
CA2003524A1 (fr) 1990-05-29
WO1990006110A1 (fr) 1990-06-14
DE68909219T2 (de) 1994-01-13
PH26677A (en) 1992-09-15
KR900701261A (ko) 1990-12-01
NL300066I1 (nl) 2001-12-01
DE19975039I2 (de) 2000-03-30
AU4620789A (en) 1990-06-26
IE61928B1 (en) 1994-11-30
KR0164435B1 (ko) 1999-01-15
AU633529B2 (en) 1993-02-04
EP0397831A1 (fr) 1990-11-22
DK177690A (da) 1990-09-13
DK177690D0 (da) 1990-07-26
CA2003524C (fr) 1999-10-19
IE893690L (en) 1990-05-29
DK175587B1 (da) 2004-12-13
US5436272A (en) 1995-07-25

Similar Documents

Publication Publication Date Title
LU91131I2 (fr) Duloxétine et ses sels d'addition acides pharmaceutiquement acceptables, et en particulier, chlorhydrate de duloxétine.
LU91452I2 (fr) "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"
LU91147I2 (fr) Pemetrexed et ses sels pharmaceutiquement acceptables.
LU90484I2 (fr) Novorapid - insuline asparte et ses sels et derives pharmaceutiquement acceptables
LU88842I2 (fr) Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
LU88576I2 (fr) RISPERIDONE et ses sels pharmaceutiquement acceptables (Risperdal R)
LU90297I2 (fr) Rivastigmine ses sels et dérivés pharmaceutiquement acceptables en particulier la rivastigmine sous forme d'hydrogénotartrate
EG18266A (en) Improvements in pharmaceutically acceptable salts
LU91650I2 (fr) Saxagliptine et sels pharmaceutiquement acceptables de celle-ci, y compris l'hydrochlorure de saxagliptine - Onglyza-saxagliptin
LU91291I2 (fr) Deferasirox et ses sels pharmaceutiquement acceptables (EXJADEr)
NO2005012I2 (no) Triptorelin og farmasoytisk akseptable salter derav
NO2001009I1 (no) Kvetiapin og farmasøytisk akseptable salter derav
NO2006004I2 (no) Erlotinib hydroklorid og farmasøytisk akseptable salter derav
LU91802I2 (fr) Telmisartan, éventuellement sous forme de sels pharmacologiquement acceptables et Amlodipine, éventuellement sous forme de sels pharmacologiquement acceptables, en particulier le bésylate d'Amlodipine
LU90865I2 (fr) Hydrochlorure d sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorure de sibutramine
LU92681I2 (fr) Nintédanib, ses tautomères et ses sels, en particulier Nintédanib et ses sels pharmaceutiquement acceptables, en particulier Nintédanib Esilate
NO932127L (no) Imidatderivater og farmasoeytisk nyttige sulfamater med antikonvulserende virkning
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
ITTO940410A0 (it) Articolo per l'introduzione in una apertura
NO308854B1 (no) Terapeutiske forbindelser, farmasøytisk akseptable salter og formuleringer inneholdende forbindelsene, samt anvendelser derav
FI905674A7 (fi) Menetelmä valmistaa farmaseuttisesti käyttökelpoisia 5,11-dihydro-6H-dipyrido/3,2-b:2',3'-e//1,4/diatsepin-6-oneja ja -tioneja
AU6644986A (en) S-(-)-1-propyl-2', 6' pipecoloxylidide hydrochloride monohydrate and a method for its preparation
NO953673L (no) [1,2,4ÅTriazolo[4,3-aÅkinoksalinderivater, deres fremstilling og anvendelse
DK473289A (da) 2'-halogenmethyliden-, 2'-ethenyliden- og 2'-ethynyl-adenosin-derivater, deres fremstilling og anvendelse
ZA895271B (en) ((4-piperidyl)methyl)-2,3-dihydro-1h-isoindole and-2,3,4,5-tetrahydro-1h-benzazepine derivatives,their preparation and their application in therapy